Recently revealed emails show Fauci and NIAID officials “scrambled in April 2020 to answer questions about altering the endpoint” in a trial of remdesivir. Once the drug was declared the new standard of care for COVID-19, as Forbes reported, Gilead’s stock surged more than 16 percent in overnight trading.
Cihlar and Lane had reason to be glad over what Fauci called “quite good news.”… Read the rest
Tag: Gilead
EXCLUSIVE: Fauci’s Agency Scrambled to Answer Questions on Changing Remdesivir Trial Endpoint: Emails
By Zachary Stieber| April 16, 2022
Dr. Anthony Fauci and top officials at the agency he heads scrambled in April 2020 to answer questions about altering the endpoint in a trial testing the antiviral drug called remdesivir, newly obtained emails show.
The endpoint was changed in the middle of the trial from measuring the effectiveness against death and various forms of hospitalization on day 15 to time to recovery through day 29.… Read the rest